抗血素缺乏和血栓形成:在一个单一机构报告的广泛临床情景
Ana Marco-Rico1,2, Pascual Marco-Vera2,3
1Hemostasis and Thrombosis Department, Hematology Service, University General Hospital Dr. Balmis, Alicante, Spain.
Journal of blood medicine
|September 7, 2023
概括
先天性抗素 (AT) 缺乏症是一种高风险的血栓友症,通常会导致早期的血栓形成. 在家庭中早期诊断对于管理这种情况和预防复发性血栓至关重要.
科学领域:
- 血液学 血液学 血液学
- 遗传学 是一个遗传学.
- 血管医学 血管医学
背景情况:
- 先天性抗素 (AT) 缺乏是血栓形成的重要危险因素.
- 临床表现因家族病史和遗传突变类型而异.
- 遗传AT缺乏症可能导致早期发病和不典型的血栓形成,包括儿科患者.
研究的目的:
- 突出早期诊断遗传性AT缺乏症在有血栓形成家族病史的人群中的重要性.
- 强调评估一级亲属的必要性,即使无症状.
- 呈现遗传AT缺乏症的不同临床演变.
主要方法:
- 病例系列介绍四名诊断为遗传AT缺乏症的无关患者.
- 对临床病史,遗传发现和血栓事件的审查.
- 分析家族史和管理策略.
主要成果:
- 确定遗传性AT缺乏症是高风险的血栓友爱症.
- 在四个病例中表现出不同的临床表现和结果.
- 强调需要主动血栓预防和长期抗凝药.
结论:
- 由于高的血栓形成风险和复发,先天性AT缺陷需要早期识别和终身管理.
- 对一级亲属的查对于全面的患者护理和预防至关重要.
- 了解临床演变的异质性是有效治疗方法的关键.
相关概念视频
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Anticoagulant Drugs: Low-Molecular-Weight Heparins
747
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
747
Venous Thrombosis I: Introduction
12
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
12
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
14
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
14
Disorders of Hemostasis
987
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
987
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


